Wiley Online Library - Click on the article title to read...
Twitter Feed: Naveen Pemmaraju, MD
ScienceDirect - Journals & BooksRegisterSign inSign inRegisterJournals & BooksHelpAccess through your institutionto view subscribed content from homeAdvancedOutlineKeywordsKey pointsIntroductionLiterature reviewMechanism of actionPreclinical developmentClinical...
-
👉👉👉Check out our state-of-the-art review article: Dr Danielle Hammond @LeukemiaMDA fellow MD @DanielleHammo20 & @doctorpemm || #Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm https://t.co/xVe6j74hBv || #BPDCN #CD123 {Editor: @lane_andy } #endcancer
American Society of Hematology Publications - Key Points. According to next-generation deep sequencing, TN patients with ET may have “low-level” driver mutations affecting JAK2 or MPL.Gene expression...
-
Important paper by Dr Samah Alimam & Professor Dr Claire Harrison .@harrisoncn1 et al 👉 Patients with triple-negative, #JAK2V617F- and #CALR-mutated ET share a unique gene expression signature | @BloodAdvances https://t.co/DGobwLIAps || #NFkB #TNF #inflammation #MPNSM https://t.co/DGobwLIAps
Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy
posted 3 weeks
Mashup Score: 3
Clinical Lymphoma, Myeloma and Leukemia - Micro-AbstractWe retrospectively analyzed the outcomes of 1412 patients with myelofibrosis stratified by bone marrow blasts and exposure to ruxolitinib (RUX). Patients with 5% to...
-
👉👉👉Our group’s newest paper ➡️ Led by Dr Lucia Masarova & Dr Verstovsek @LeukemiaMDA || Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis & the Effect of Ruxolitinib Therapy https://t.co/rjRWqFHvjW | #MPNSM #leusm @MDAndersonNews #endcancer
Targeted Oncology - In an interview with Targeted Oncology, Naveen Pemmaraju, MD, discussed recent advances for the treatment of patients with MPNs and shared his thoughts on...
-
👉👉👉Virtual Meetings Open Up Online Communication for MPNs | check out my interview w/ @TargetedOnc w/shout outs to : @mpdrc @jjkiladjian @harrisoncn1 @DavidSteensma | #MPNSM @LeukemiaMDA https://t.co/1dh63rZweR
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
posted 2 weeks
Mashup Score: 1
Blood Cancer Journal - FLT3 mutations occur in 20–35% patients with newly diagnosed (ND) acute myeloid leukemia (AML) and confer a higher risk of relapse and inferior overall...
-
👉👉👉Our group’s new paper by Dr Maiti & Dr Konopleva |Triplet therapy w/venetoclax,FLT3 inhibitor &decitabine for FLT3+AML | #BCJ #OpenAccess @VincentRK | @NitinJainMD @TapKadia @DrKTakahashi @Daver_Leukemia #leusm https://t.co/V5Og8T96Ce
New York Times - With whipsawing trades and other player movement routine in the N.B.A. these days, it’s hard to be loyal to teams and...
-
Beautiful article by .@kurtstreeter in @nytimes ! Fresh prose, touching, moving, evocative writing ✍️ style. Make sure to check out this gem of an essay #SportsAndSociety @NBA @espn @KDTrey5 @JHarden13 https://t.co/2OQegrX9Cp
Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms
posted 2 weeks
Mashup Score: 1
Taylor & Francis - (2020). Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. Leukemia & Lymphoma. Ahead of...
-
Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms https://t.co/YnDXzArez2 || #BRDi #BRD4 #Bromodomain #leusm #BPDCN #MPNSM @LeukemiaMDA
Treating Rosai–Dorfman disease and RAS‐associated autoimmune leucoproliferative disorder with malignant transformation
posted 2 weeks
Mashup Score: 1
Wiley Online Library - The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images...
-
Treating Rosai–Dorfman disease and RAS‐associated autoimmune leucoproliferative disorder with malignant transformation https://t.co/ec6teIMQpe || #leusm #MPNSM #RDD #RALD #bmtsm @LeukemiaMDA
Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission
posted 4 weeks
Mashup Score: 1
American Cancer Society Journals - Lenalidomide maintenance in patients with high‐risk acute myeloid leukemia results in a 2‐year overall survival rate of 63%. The beneficial effect is most profound...
-
Congrats to the brilliant Dr .@ImanAboudalle @AUB_Lebanon leading w/@TapKadia Ph2 #lenalidomide maintenance for patients w/high‐risk AML in remission https://t.co/MyJcQGADpH | @JournalCancer @DrFadloKhuri @garciamanero @Daver_Leukemia @SaWangMD @NitinJainMD @GCC_Cortes #leusm
Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis—TAFRO syndrome https://t.co/78Hbptv9l6 | @doctorpemm @sanamloghavi #Castleman #TAFRO